TENXTENAX THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of TENAX THERAPEUTICS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TENX본 종목 | $70M#9 | — | 0.6x#3 | — | — | -198.9%#16 | — | -46.3%#6 | — | — | -70.3%#14 | — |
| LFVN | $77M#4 | 15.4x#3 | 2.3x#9 | 0.4x#1 | -20.1%#4 | -48.3%#12 | 3.3%#3 | 15.1%#3 | 28.2%#1 | 6#1 | -40.8%#13 | 3.0%#1 |
| GANX | $77M#2 | — | 6.9x#12 | 1403.9x#6 | -58.4%#5 | 1.2%#8 | -33908.5%#6 | -178.5%#12 | — | — | 12.0%#4 | — |
| TELO | $77M#3 | — | 15.4x#14 | — | — | 37.0%#4 | — | -206.9%#13 | — | — | -16.0%#8 | — |
| LEXX | $77M#5 | — | 16.3x#15 | 109.2x#4 | 52.0%#2 | -105.4%#14 | -1683.0%#4 | -251.2%#14 | — | — | -82.8%#15 | — |
| CING | $74M#6 | — | 3.2x#10 | — | — | -35.6%#11 | — | -95.7%#10 | — | — | 36.8%#3 | — |
| ACRV | $73M#7 | — | 0.8x#4 | — | — | 3.3%#7 | — | -89.9%#8 | — | — | 8.6%#5 | — |
| PLRX | $70M#8 | — | 0.5x#1 | — | — | -29.0%#10 | — | 101.6%#1 | — | — | -22.9%#10 | — |
| CALC | $68M#10 | — | 12.4x#13 | — | — | -115.8%#15 | — | -536.2%#15 | — | — | -87.4%#16 | — |
| RNTX | $68M#11 | — | 1.2x#7 | — | — | 20.7%#5 | — | -90.4%#9 | — | — | -29.1%#11 | — |
| XBIT | $66M#12 | — | 0.5x#2 | — | -100.0%#7 | -18.2%#9 | — | -35.5%#4 | — | — | -17.8%#9 | — |
| SPRO | $66M#13 | 8.1x#2 | 1.5x#8 | 5.2x#3 | 3292.5%#1 | 112.5%#1 | 50.2%#1 | 19.4%#2 | — | — | -40.2%#12 | — |
| EVFM | $63M#14 | — | — | 3.1x#2 | 4.2%#3 | 104.4%#2 | 16.7%#2 | — | — | — | 0.3%#6 | — |
| BOLD | $63M#15 | — | 1.0x#6 | — | — | 11.0%#6 | — | -88.2%#7 | — | — | 141.3%#1 | — |
| IBIO | $81M#1 | — | 0.9x#5 | 810.3x#5 | -75.0%#6 | -78.7%#13 | -35141.0%#7 | -38.3%#5 | — | — | 49.8%#2 | — |
| IBO | $63M#16 | 0.7x#1 | 5.8x#11 | 1954.3x#7 | — | 52.1%#3 | -13381.3%#5 | -110.0%#11 | -18.9%#2 | — | -13.0%#7 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice